Acrivon Therapeutics, Inc. (ACRV) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2025. Acrivon Therapeutics is a clinical-stage biotechnology company focused on oncology, utilizing its proprietary AP3 precision medicine platform. The company is advancing two primary clinical assets: ACR-368 (prexasertib), a CHK1/CHK2 inhibitor in a registrational Phase 2 trial for endometrial cancer, and ACR-2316, a WEE1/PKMYT1 inhibitor in Phase 1 studies. The company has no approved products and has not generated any revenue from drug sales.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(21,006) | $(18,798) | $(40,686) | $(35,284) |
| Net Loss Per Share (Basic/Diluted) | $(0.55) | $(0.52) | $(1.06) | $(1.20) |
| Operating Expenses | $22,649 | $21,437 | $44,311 | $39,105 |
| Research & Development (R&D) | $16,182 | $15,025 | $31,596 | $26,498 |
| General & Administrative (G&A) | $6,467 | $6,412 | $12,715 | $12,607 |
| Cash, Cash Equivalents & Investments | $147.6 million (as of June 30, 2025) | |||
| Accumulated Deficit | $237.7 million (as of June 30, 2025) | |||
| Net Cash Used in Operating Activities | N/A | $(36,145) | $(30,986) |
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by $2.2 million for Q2 2025 compared to Q2 2024, and by $5.4 million for the six-month period. This was driven primarily by higher operating expenses.
- R&D Expense Growth: R&D expenses increased by $1.2 million in Q2 and $5.1 million YTD. The increase is attributed to:
- Initiation of clinical trial activities for the new asset ACR-2316 (costs of $1.8M in Q2 and $2.9M YTD), which was previously grouped under preclinical discovery.
- Increased personnel-related costs due to headcount growth.
- Offset by lower milestone payments related to the ACR-368 companion diagnostic agreement compared to the prior year.
- Investment Portfolio: Short-term investments decreased from $139.7 million (Dec 31, 2024) to $95.5 million (June 30, 2025), while long-term investments increased from $5.1 million to $10.2 million, reflecting portfolio rebalancing.
- Interest Income: Interest income decreased in both Q2 and YTD periods due to lower accretion and interest earned on investments compared to the prior year.
Guidance, Outlook, and Risks
- Clinical Progress:
- ACR-368: Reported positive data in March 2025 for endometrial cancer, showing a 35% confirmed overall response rate (ORR) and 80% tumor shrinkage in biomarker-positive patients. A new Phase 2 trial combining ACR-368 with ultra low-dose gemcitabine (ULDG) for biomarker-negative patients was initiated in July 2025.
- ACR-2316: Phase 1 trial initiated in Q3 2024. Significant drug target engagement observed at Dose Level 1. Initial clinical activity observed, including a confirmed partial response in an endometrial cancer patient. A clinical data update is anticipated in the second half of 2025.
- Liquidity and Runway: Management believes existing cash, cash equivalents, and investments of $147.6 million are sufficient to fund operations into the second quarter of 2027. No sales have been made under the ATM program as of June 30, 2025.
- Risks and Contingencies:
- Capital Needs: The company expects to incur significant losses for the foreseeable future and will require additional funding to support development and commercialization efforts beyond 2027.
- Regulatory Uncertainty: Success depends on obtaining regulatory approval for ACR-368 and ACR-2316, which is not guaranteed.
- Partnership Changes: Akoya Biosciences, the partner for the ACR-368 OncoSignature test, was acquired by Quanterix Corporation in July 2025; the company does not anticipate changes to the agreement terms.
- Tax Legislation: New U.S. tax legislation (OBBBA) signed in July 2025 is being evaluated for potential impact on financial statements.
Key Facts for Investor Verification
- Runway Validation: Verify the accuracy of the projected cash runway into Q2 2027 given the current burn rate of approximately $36 million per six months in operating cash flow.
- ACR-368 Trial Data: Confirm the durability of the 35% ORR and 80% tumor shrinkage rates reported in the endometrial cancer Phase 2 trial and the enrollment progress of the new ULDG combination trial.
- ACR-2316 Milestones: Monitor the upcoming clinical data update expected in H2 2025 for safety, tolerability, and dose recommendation.
- Capital Raising: Assess the company's ability to raise additional capital in the current market environment, noting that no funds have been raised via the ATM program since its inception.
- Stock-Based Compensation: Note the significant non-cash expense ($7.7 million YTD) and the remaining unrecognized stock-based compensation of $20.5 million ($14.6M for options, $5.9M for RSUs) which will impact future earnings.